Prostate Cancer

Recommendations for using AR-targeted therapy as an approach when managing patients with metastatic castrate-sensitive prostate cancer.

The FDA granted a Fast Track designation to RV001 for the potential treatment of patients with prostate cancer.

During a Targeted Oncology Case Based Peer Perspectives event, Alicia K. Morgans, MD, MPH, reviewed 2 cases of patients with nonmetastatic castration resistant prostate cancer and explained the potential testing and treatment options.

In an interview with Targeted Oncology, Sarki Abdulkadir, MD, PhD, discussed the emerging role of the MYC protein as a target for the treatment of patients with prostate cancer.

Monica L. Baskin, PhD, addresses the biggest challenges in treating patients with prostate cancer during the COVID-19 era.

The FDA expanded approval of FoundationOne® Liquid CDx as a companion diagnostic for olaparib, which is currently indicated for use as treatment in patients with BRCA1/2 and/or ATM alterations in metastatic castration-resistant prostate cancer.

In the treatment landscape of metastatic castration resistant prostate cancer, the introduction of PARP inhibitors as a therapeutic option has led to progress, explained Maha Hussain, MD, in a presentation during the 38th Annual Chemotherapy Foundation Symposium.

A statistically significant increase in the 10-year cumulative incidence of disease progression and definitive treatment among African American men compared with non-Hispanic Caucasian men with low-risk prostate cancer.

The FDA lifted a partial clinical hold on the phase 1 P-PSMA-101-001 clinical trial of the chimeric antigen receptor T product P-PSMA-101, which is a potential treatment for patients with metastatic castration-resistant prostate cancer.

In an interview with Targeted Oncology, Naomi Haas, MD, discussed the role of PSMA in the treatment landscape of prostate cancer and highlighted the key findings from the phase 1 chimeric antigen receptor T-cell trial in metastatic castration resistance prostate cancer.

In a presentation during the 27th Annual Prostate Cancer Foundation Scientific Retreat, W. Kevin Kelly, DO, explained the potential of this novel agent and its development progress.

The bispecific T‐cell engager, AMG 160, demonstrated a manageable safety profile and preliminary evidence of efficacy in heavily pretreated patients with metastatic castration-resistant prostate cancer in a 2-part, phase 1 open-label study.

During a Targeted Oncology Case Based Peer Perspectives event, Neeraj Agarwal, MD, discussed the case of a 57-year-old male patient with nonmetastatic castration resistant prostate cancer.

A novel tubulin inhibitor VERU-111 has demonstrated promising early antitumor activity and tolerability in men with metastatic castration-resistant prostate cancer who have failed prior androgen receptor therapy, according to the results of a phase 1b/2 study.

Split-dosing of BXCL701 at 0.6 mg per day is a supported dosing strategy for the agent in combination with pembrolizumab as treatment of patients with metastatic castration-resistant prostate cancer, according to phase 1b/2 study results.

In a phase 2 trial, onvansertib, a polo-like kinase 1 inhibitor, combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have early abiraterone resistance, demonstrated a decent safety profile across 3 dosing schedules and efficacy in the evaluable arms.

CART-PSMA-TGFβRd as adoptive chimeric antigen receptor T-cell therapy administered as treatment of patients with metastatic castration-resistant prostate cancer appears safe and feasible.

A significant reduction in the risk of death was observed with the addition of sipuleucel-T to either abiraterone acetate or enzalutamide as treatment of patients with metastatic castration-resistant prostate cancer in a real-world analysis.

Neal D. Shore, MD, FACS, discusses the results of the retrospective review on real-world patterns of genomic testing in patients with metastatic castration-resistant prostate cancer.

Relugolix demonstrated a similar rate of castration resistance-free survival compared with the current standard of care leuprolide acetate as treatment of patients with metastatic prostate cancer.

Alicia K. Morgans, MD, MPH, discussed the case of a 75-year-old male with metastatic castration-resistant prostate cancer.

AMG 160 showed preliminary evidence of efficacy with a manageable safety profile as treatment of patients with metastatic castration-resistant prostate cancer who have been heavily pretreated.

A primary analysis from the phase 3 IPATential150 trial demonstrated the benefit of the addition of ipatasertib to abiraterone acetate and prednisone in the treatment of patients with metastatic castration-resistant prostate cancer with PTEN loss, according to results presented at the 2020 ESMO Virtual Congress.

Updated findings from the randomized, open-label phase 3 PROfound trial indicate that olaparib induces a significantly longer duration of overall survival versus enzalutamide or abiraterone plus prednisone in metastatic castration-resistant prostate cancer tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and disease that has progressed during previous treatment with a next-generation hormonal agent.